Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear-cell renal cell carcinoma treated with radical or partial nephrectomy.

Tanaka, Ryuma; Hatakeyama, Shingo; Miura, Hikari; Hamaya, Tomoko; Yoneyama, Takahiro; Ohyama, Chikara

Tanaka, Ryuma; Hatakeyama, Shingo; Miura, Hikari; Hamaya, Tomoko; Yoneyama, Takahiro; Ohyama, Chikara.

Afiliação

Tanaka R; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hatakeyama S; Department of Urology, Mutsu General Hospital, Mutsu, Japan.
Miura H; Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hamaya T; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Yoneyama T; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Ohyama C; Department of Urology, Mutsu General Hospital, Mutsu, Japan.

Int J Urol ; 29(10): 1235-1237, 2022 10.

Article em En | MEDLINE | ID: mdl-35697523

Assuntos

Carcinoma de Células Renais; Neoplasias Renais; Carcinoma de Células Renais/patologia; Carcinoma de Células Renais/cirurgia; Humanos; Imunoterapia; Neoplasias Renais/patologia; Neoplasias Renais/cirurgia; Nefrectomia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Limite: Humans Idioma: En Revista: Int J Urol Assunto da revista: UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google